References
- Raje N., Powles R., Kulkarni S., Milan S., Middleton G., Singhal S., Mehta J., Millar B., Viner C., Raymond J., Treleaven J., Cunningham D., Gore M. A comparison of vincristine and doxorubicin infusional chemotherapy with methylprednisolone (VAMP) with the addition of weekly cyclophosphamide (C-VAMP) as induction treatment followed by autografting in previously untreated myeloma. British Journal of Haematology 1997; 97: 153–160
- Cunningham D., Paz-Ares L., Milan S., Powles R., Nicholson M., Hickish T., Selby P., Treleaven J., Viner C., Malpas J., Slevin M., Findly M., Raymond J., Gore M. E. High dose melphalan and autologous bone marrow transplantation as consolidation in previously untreated myeloma. Journal of Clinical Oncology 1994; 12: 759–763
- Di Marco A., Zunino F., Casazza A. M. Comparison of biochemical and biological methods in the evaluation of new anthracycline drugs. Antibiotic Chemotherapy 1978; 23: 12–20
- Casazza A. M., Pratesi G., Giuliani F., Di Marco A. Antileukaemic activity of 4-demethoxydaunorubicin in mice. Tumori 1980; 66: 549–564
- Carella A. M., Santini G., Martinengo M. 4-demethoxydaunorubicin in refractory or relapses acute leukaemias: a pilot study. Cancer 1985; 55: 1452–1454
- Lopez M., Lazzaro B., Di Ianzo L., Papaldo P. Activity of oral 4 demethoxydaunorubicin in non-Hodgkin's Lymphoma. 14th International Congress of Chemotherapy. KyotoJapan 1985; 39, WS-410
- Chisesi T., Capnist G., Dominicis E., Dini E. A Phase II study of Idarubicin (4-demethoxydaunorubicn) in advanced myeloma. European Journal Cancer 1988; 24: 681–684
- Gore M. E., Selby P., Viner C., Clark P. I., Meldrum M., Millar B., Bell J., Maitland J., Milan S., Judson I., Zuiable A., Tillyer C., Slevin M., Malpas J., McElwain T. J. Intensive treatment for multiple myeloma and criteria for complete remission. Lancet 1989; ii: 879–882
- Cook G., Sharp A., Tansey P., Franklin I. M. A Phase I/II trial of Z-Dex (oral idarubicin and dexamethasone), an oral equivalent of VAD, as initial therapy at diagnosis or progression in multiple myeloma. British Journal of Haematology 1996; 93: 931–934
- Glasmacher A., Haferlach T., Gorschluter M., Mezger J., Maintz C., Clemens M. R., Ko Y., Hahn C., Ubelacker R., Kleinschmidt R., Gieseler F. Oral idarubicin, dexamethasone and vincristine (VID) in the treatment of multiple myeloma. Leukemia 1997; 11(Suppl 5)s22–6